The opposing results of SMAD1 expression in MM6 cells demonstrate that TGF-β signaling can have diverse outcomes in KMT2A-rearranged leukemia, compatible with the versatile nature of TGF-β signaling (20, 68). This evidence concerns the gene TGFB1 and leukemia.